Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 433

The DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Open access
Sbidian, Emilie, Chaimani, Anna, Garcia-Doval, Ignacio, Do, Giao, Hua, Camille, Mazaud, Canelle, Droitcourt, Catherine, Hughes, Carolyn, Ingram, John R, Naldi, Luigi, Chosidow, Olivier, Le Cleach, Laurence·2017·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Several randomised controlled trials (RCTs) have compared the efficacy of the different systemic treatments in psoriasis against placebo. However, the relative benefit of these treatments remains unclear due to the limited number of trials comparing them directly head-to-head, which is why we chose to conduct a network meta-analysis. OBJECTIVES: To compare the efficacy and safety of non-biological systemic agents, small molecules, and biologics for people with moderate-to-severe psoriasis using a network meta-analysis, and to provide a ranking of these treatments according to their efficacy and safety. SEARCH METHODS: For this living systematic review we updated our searches of the following databases monthly to September 2020: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase. We searched two trials registers to the same date. We checked the reference lists of included studies and relevant systematic reviews for further references to eligible RCTs. SELECTION CRITERIA: Randomised controlled trials (RCTs) of systemic treatments in adults (over 18 years of age) with moderate-to-severe plaque psoriasis or psoriatic arthritis whose skin had been clinically diagnosed with moderate-to-severe psoriasis, at any stage of treatment, in comparison to placebo or another active agent. The primary outcomes of this review were: the proportion of participants who achieved clear or almost clear skin, that is, at least Psoriasis Area and Severity Index (PASI) 90 at induction phase (from 8 to 24 weeks after the randomisation), and the proportion of participants with serious adverse events (SAEs) at induction phase. We did not evaluate differences in specific adverse events. DATA COLLECTION AND ANALYSIS: Several groups of two review authors independently undertook study selection, data extraction, 'Risk of bias' assessment, and analyses. We synthesised the data using pair-wise and network meta-analysis (NMA) to compare the treatments of interest and rank them according to their effectiveness (as measured by the PASI 90 score) and acceptability (the inverse of serious adverse events). We assessed the certainty of the body of evidence from the NMA for the two primary outcomes and all comparisons, according to CINeMA, as either very low, low, moderate, or high. We contacted study authors when data were unclear or missing. We used the surface under the cumulative ranking curve (SUCRA) to infer on treatment hierarchy: 0% (treatment is the worst for effectiveness or safety) to 100% (treatment is the best for effectiveness or safety). MAIN RESULTS: We included 158 studies (18 new studies for the update) in our review (57,831 randomised participants, 67.2% men, mainly recruited from hospitals). The overall average age was 45 years; the overall mean PASI score at baseline was 20 (range: 9.5 to 39). Most of these studies were placebo-controlled (58%), 30% were head-to-head studies, and 11% were multi-armed studies with both an active comparator and a placebo. We have assessed a total of 20 treatments. In all, 133 trials were multicentric (two to 231 centres). All but two of the outcomes included in this review were limited to the induction phase (assessment from 8 to 24 weeks after randomisation). We assessed many studies (53/158) as being at high risk of bias; 25 were at an unclear risk, and 80 at low risk. Most studies (123/158) declared funding by a pharmaceutical company, and 22 studies did not report their source of funding. Network meta-analysis at class level showed that all of the interventions (non-biological systemic agents, small molecules, and biological treatments) were significantly more effective than placebo in reaching PASI 90. At class level, in reaching PASI 90, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the non-biological systemic agents. At drug level, infliximab, ixekizumab, secukinumab, brodalumab, risankizumab and guselkumab were significantly more effective in reaching PASI 90 than ustekinumab and three anti-TNF alpha agents: adalimumab, certolizumab, and etanercept. Ustekinumab and adalimumab were significantly more effective in reaching PASI 90 than etanercept; ustekinumab was more effective than certolizumab, and the clinical effectiveness of ustekinumab and adalimumab was similar. There was no significant difference between tofacitinib or apremilast and three non-biological drugs: fumaric acid esters (FAEs), ciclosporin and methotrexate. Network meta-analysis also showed that infliximab, ixekizumab, risankizumab,

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd011535.pub2

Cites

327 of 327 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 327 references

Research works printed but not linked: 259

  1. Akcali, 2014, Serum concentrations of interleukin-2 and tumour necrosis factor-alpha under cyclosporine versus acitretin treatment in plaque-type psoriasis, Journal of International Medical Research, 42, 1118, 10.1177/0300060514539280 · doi:10.1177/0300060514539280
  2. Al-Hamamy, 2014, Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis, International Journal of Dermatology, 53, 1531, 10.1111/ijd.12444 · doi:10.1111/ijd.12444
  3. Bagel, 2011, Etanercept therapy for moderate to severe plaque psoriasis with involvement of the scalp, Journal of the American Academy of Dermatology, 64, AB150
  4. Chladek, 2005, Low-dose methotrexate pharmacokinetics and pharmacodynamics in the therapy of severe psoriasis, Basic & Clinical Pharmacology & Toxicology, 96, 247, 10.1111/j.1742-7843.2005.pto960318.x · doi:10.1111/j.1742-7843.2005.pto960318.x
  5. Dogra, 2012, Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study, Clinical and Experimental Dermatology, 37, 729, 10.1111/j.1365-2230.2012.04440.x · doi:10.1111/j.1365-2230.2012.04440.x
  6. Dogra, 2013, Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: A randomized, double blind, parallel group, dose ranging study, Journal of the European Academy of Dermatology and Venereology : JEADV, 27, e305, 10.1111/j.1468-3083.2012.04644.x · doi:10.1111/j.1468-3083.2012.04644.x
  7. Dubertret, 1989, Cyclosporin in psoriasis. A long-term randomized study on 37 patients, Acta Dermato-Venereologica, Supplement, 69, 136
  8. Ellis, 2003, Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial, American Journal of Clinical Dermatology, 4, 131, 10.2165/00128071-200304020-00005 · doi:10.2165/00128071-200304020-00005
  9. Engst, 1994, Long-term cyclosporin A for psoriasis, Acta Dermatovenerologica Alpina, Panonica et Adriatica, 3, 188
  10. Fallah Arani, 2011, Fumarates vs. Methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial, British Journal of Dermatology, 164, 855, 10.1111/j.1365-2133.2010.10195.x · doi:10.1111/j.1365-2133.2010.10195.x
  11. Gupta, 1989, Side-effect profile of acitretin therapy in psoriasis, Journal of the American Academy of Dermatology, 20, 1088, 10.1016/S0190-9622(89)70138-9 · doi:10.1016/s0190-9622(89)70138-9
  12. Gottlieb, 2011, Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis, British Journal of Dermatology, 165, 652, 10.1111/j.1365-2133.2011.10418.x · doi:10.1111/j.1365-2133.2011.10418.x
  13. Griffiths, 2015, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials, Lancet, 386, 541, 10.1016/S0140-6736(15)60125-8 · DOI · Paper page
  14. Kerkhof, 2017, Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3, Journal of the European Academy of Dermatology and Venereology : JEADV, 31, 477, 10.1111/jdv.14033 · doi:10.1111/jdv.14033
  15. Gurel, 2015, A single-blind study comparing acitretin and narrow-band UVB with the combination of placebo and narrow-band UVB in the treatment of plaque-type psoriasis, Türkderm, 49, 2, 10.4274/turkderm.54771 · doi:10.4274/turkderm.54771
  16. Opmeer, 2004, Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine, Archives of Dermatology, 140, 685, 10.1001/archderm.140.6.685 · doi:10.1001/archderm.140.6.685
  17. Hunter, 1963, Methotrexate in the treatment of psoriasis: a controlled clinical trial, Australasian Journal of Dermatology, 7, 91, 10.1111/j.1440-0960.1963.tb01685.x · doi:10.1111/j.1440-0960.1963.tb01685.x
  18. Igarashi, 2012, Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial, Journal of Dermatology, 39, 242, 10.1111/j.1346-8138.2011.01347.x · doi:10.1111/j.1346-8138.2011.01347.x
  19. Jacobe, 2008, The role of narrowband UV-B plus alefacept combination therapy in the treatment of psoriasis, Archives of Dermatology, 144, 1067-8; author, 10.1001/archderm.144.8.1067 · doi:10.1001/archderm.144.8.1067
  20. Krueger, 2003, Clinical response to alefacept: Results of a phase 3 study of intravenous administration of alefacept in patients with chronic plague psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 17, 17, 10.1046/j.1468-3083.17.s2.4.x · doi:10.1046/j.1468-3083.17.s2.4.x
  21. Menter, 2006, The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis, Journal of the American Academy of Dermatology, 54, 61, 10.1016/j.jaad.2005.10.006 · doi:10.1016/j.jaad.2005.10.006
  22. Laburte, 1994, Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis, British Journal of Dermatology, 130, 366, 10.1111/j.1365-2133.1994.tb02935.x · doi:10.1111/j.1365-2133.1994.tb02935.x
  23. Langley, 2014, Secukinumab in plaque psoriasis--results of two phase 3 trials, The New England Journal of Medicine, 371, 326, 10.1056/NEJMoa1314258 · DOI · Paper page
  24. Finlay, 2003, Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis, Dermatology (Basel, Switzerland), 206, 307, 10.1159/000069942 · doi:10.1159/000069942
  25. Ortonne, 2003, Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patient with chronic plaque psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 17, 12, 10.1046/j.1468-3083.17.s2.3.x · doi:10.1046/j.1468-3083.17.s2.3.x
  26. Ortonne, 2003, Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis, European Journal of Dermatology, 13, 117
  27. Lebwohl, 2015, Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, New England Journal of Medicine, 373, 1318, 10.1056/NEJMoa1503824 · DOI · Paper page
  28. Gordon, 2006, Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.[Erratum appears in J Dermatolog Treat. 2006;17(3):192], Journal of Dermatological Treatment, 17, 9, 10.1080/09546630500472838 · doi:10.1080/09546630500472838
  29. Krueger, 2006, Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial, Journal of the American Academy of Dermatology, 54, S112, 10.1016/j.jaad.2005.10.054 · doi:10.1016/j.jaad.2005.10.054
  30. Langley, 2015, Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 29, 1763, 10.1111/jdv.12996 · doi:10.1111/jdv.12996
  31. Tham, 2014, Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis, Journal of Clinical Pharmacology, 54, 1117, 10.1002/jcph.312 · doi:10.1002/jcph.312
  32. Zhu, 2013, Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis, British Journal of Dermatology, 169, 1337, 10.1111/bjd.12610 · doi:10.1111/bjd.12610
  33. Hu, 2011, Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis, Journal of Pharmacokinetics and Pharmacodynamics, 38, 237, 10.1007/s10928-011-9191-7 · doi:10.1007/s10928-011-9191-7
  34. Lebwohl, 2010, Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial, British Journal of Dermatology, 162, 137, 10.1111/j.1365-2133.2009.09491.x · doi:10.1111/j.1365-2133.2009.09491.x
  35. Reich, 2012, An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up, Journal of Drugs in Dermatology, 11, 300
  36. Rich, 2014, Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: Results from PHOENIX 1, British Journal of Dermatology, 170, 398, 10.1111/bjd.12632 · doi:10.1111/bjd.12632
  37. Meffert, 1997, Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile, Acta Dermato-Venereologica, 77, 137, 10.2340/0001555577137141 · doi:10.2340/0001555577137141
  38. Reich, 2007, Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis, European Journal of Dermatology, 17, 381
  39. Reich, 2010, Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: A retrospective analysis of the EXPRESS trial, Dermatology, 221, 172, 10.1159/000317775 · doi:10.1159/000317775
  40. Armstrong, 2016, Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab, American Journal of Clinical Dermatology, 17, 691, 10.1007/s40257-016-0229-x · doi:10.1007/s40257-016-0229-x
  41. Nugteren-Huying, 1990, Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study, Nederlands Tijdschrift voor Geneeskunde, 134, 2387
  42. Ortonne, 2013, A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis, British Journal of Dermatology, 168, 1080, 10.1111/bjd.12060 · doi:10.1111/bjd.12060
  43. Gordon, 2014, Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: Use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory, British Journal of Dermatology, 170, 705, 10.1111/bjd.12636 · doi:10.1111/bjd.12636
  44. Papp, 2015, Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis, Journal of the American Academy of Dermatology, 72, 436, 10.1016/j.jaad.2014.10.026 · doi:10.1016/j.jaad.2014.10.026
  45. Mamolo, 2014, Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 28, 192, 10.1111/jdv.12081 · doi:10.1111/jdv.12081
  46. Mamolo, 2015, Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses, Journal of Dermatological Treatment, 26, 121, 10.3109/09546634.2014.906033 · doi:10.3109/09546634.2014.906033
  47. Sigurgeirsson, 2014, Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: Subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study, Journal of the European Academy of Dermatology and Venereology : JEADV, 28, 1127, 10.1111/jdv.12343 · doi:10.1111/jdv.12343
  48. Rich, 2016, Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)., Journal of the American Academy of Dermatology, 74, 134, 10.1016/j.jaad.2015.09.001 · doi:10.1016/j.jaad.2015.09.001
  49. Papp, 2015, Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials, British Journal of Dermatology, 173, 949, 10.1111/bjd.14018 · DOI · Paper page
  50. Langley, 2015, Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: Results from the PHOENIX 2 study through 5 years of follow-up, British Journal of Dermatology, 172, 1371, 10.1111/bjd.13469 · doi:10.1111/bjd.13469
  51. Piskin, 2003, Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ, Archives of Dermatological Research, 294, 559, 10.1007/s00403-002-0353-8 · doi:10.1007/s00403-002-0353-8
  52. Paul, 2014, Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: Subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial, Journal of the European Academy of Dermatology and Venereology : JEADV, 28, 1670, 10.1111/jdv.12359 · doi:10.1111/jdv.12359
  53. Sandhu, 2003, Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India, Journal of Dermatology, 30, 458, 10.1111/j.1346-8138.2003.tb00416.x · doi:10.1111/j.1346-8138.2003.tb00416.x
  54. Navarini, 2014, Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis, Journal of Drugs in Dermatology, 13, 554
  55. Reich, 2010, Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial, Journal of the American Academy of Dermatology, 63, 1011, 10.1016/j.jaad.2009.12.029 · doi:10.1016/j.jaad.2009.12.029
  56. Saurat, 2011, Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study, British Journal of Dermatology, 165, 399, 10.1111/j.1365-2133.2011.10399.x · doi:10.1111/j.1365-2133.2011.10399.x
  57. Shehzad, 2004, Efficacy of concomitant use of puva and methotrexate in disease clearance time in plaque type psoriasis, Journal of the Pakistan Medical Association, 54, 453
  58. Kirkham, 2015, Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial, Clinical and Experimental Rheumatology, 33, 11
  59. Prinz, 2011, Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial, Journal of the European Academy of Dermatology and Venereology : JEADV, 25, 559, 10.1111/j.1468-3083.2010.03838.x · doi:10.1111/j.1468-3083.2010.03838.x
  60. Sterry, 2010, Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial, BMJ (Clinical Research Ed.), 340, c147, 10.1136/bmj.c147 · doi:10.1136/bmj.c147
  61. Strohal, 2013, The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial), Journal of Dermatological Treatment, 24, 169, 10.3109/09546634.2012.658015 · doi:10.3109/09546634.2012.658015
  62. Torii, 2010, Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial, Journal of Dermatological Science, 59, 40, 10.1016/j.jdermsci.2010.04.014 · doi:10.1016/j.jdermsci.2010.04.014
  63. Tsai, 2012, Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial, Journal of Drugs in Dermatology, 11, 943
  64. Chimenti, 2013, A phase II study of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in chronic plaque psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 27, 22
  65. Kemeny, 2013, A phase II study of ponesimod in chronic plaque psoriasis: Improvements in patient-reported outcomes, Journal of the European Academy of Dermatology and Venereology : JEADV, 27, 21
  66. Kerkhof, 2008, Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension, British Journal of Dermatology, 159, 1177
  67. Yan, 2011, Treatment of psoriasis with recombinant human LFA3-antibody fusion protein: a multi-center, randomized, double-blind trial in a Chinese population, European Journal of Dermatology, 21, 737, 10.1684/ejd.2011.1465 · doi:10.1684/ejd.2011.1465
  68. Yang, 2012, Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial, Chinese Medical Journal, 125, 1845
  69. Yilmaz, 2002, Re-PUVA therapy for psoriasis vulgaris: an effective choice, Journal of the European Academy of Dermatology and Venereology : JEADV, 16, 258
  70. Yılmaz, 2002, Re-PUVA therapy for psoriasis vulgaris: an effective choice, Türkiye Klinikleri Dermatoloji Dergisi, 12, 204
  71. Zheng, 2012, A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results, Journal of Dermatology, 39, 238
  72. Zhu, 2013, Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS), Journal of Drugs in Dermatology, 12, 166
  73. Zhu, 2014, Ustekinumab improves health-related quality of life in Chinese patients with moderate-to-severe plaque psoriasis: Results from the LOTUS trial and curative effect observation, Journal of Clinical Dermatology, 43, 521
  74. Abufarag, 2010, Selective activation of naturally occurring regulatory T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity in psoriasis: Early clinical results after single doses, Journal of Investigative Dermatology, 130, S64
  75. Akhyani, 2010, Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 24, 1447, 10.1111/j.1468-3083.2010.03667.x · doi:10.1111/j.1468-3083.2010.03667.x
  76. Angsten, 2007, Anti-TNF-alpha-therapy of psoriasis with Infliximab or Etanercept. Clinical, histological and immunohistochemical course, Aktuelle Dermatologie, 33, 310, 10.1055/s-2007-966548 · doi:10.1055/s-2007-966548
  77. Anonymous, 2005, Aldalimumab in psoriatic arthritis and as the initial therapy in rheumatoid arthritis, Krankenpflege Journal, 43, 244
  78. Anonymous, 2008, Trial watch: novel biologic for psoriasis shows superiority over current best-seller, Nature Reviews. Drug Discovery, 7, 880
  79. Arifov, 1998, Acitretin (neotigason) in the treatment of psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 11, S290, 10.1016/S0926-9959(98)95686-0 · doi:10.1016/s0926-9959(98)95686-0
  80. Armati, 1972, Retinoic acid for psoriasis, Australasian Journal of Dermatology, 13, 79, 10.1111/j.1440-0960.1972.tb00490.x · doi:10.1111/j.1440-0960.1972.tb00490.x
  81. Bagot, 1994, Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis, Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie, 317, 282
  82. Barzegari, 2004, Comparison of bath PUVA and acitretin in treatment of psoriatic patients, Iranian journal of dermatology, 7, 31
  83. Batchelor, 2009, Adalimumab vs methotrexate for the treatment of chronic plaque psoriasis, Archives of Dermatology, 145, 704, 10.1001/archdermatol.2009.104 · doi:10.1001/archdermatol.2009.104
  84. Bayerl, 1992, Treatment of psoriasis vulgaris with etretinate versus cyclosporin A. Report on a study., Aktuelle Dermatologie, 18, 27
  85. Beissert, 2009, A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis, Dermatology (Basel, Switzerland), 219, 126, 10.1159/000226134 · doi:10.1159/000226134
  86. Berbis, 1989, Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis, Dermatologica, 178, 88, 10.1159/000248398 · doi:10.1159/000248398
  87. Bhuiyan, 2010, Role of oral colchicine in plaque type psoriasis. A randomized clinical trial comparing with oral methotrexate, Journal of Pakistan Association of Dermatologists, 20, 146
  88. Bigby, 2004, A randomized controlled trial of methotrexate and cyclosporine in the treatment of psoriasis, Archives of Dermatology, 140, 347, 10.1001/archderm.140.3.347 · doi:10.1001/archderm.140.3.347
  89. Bjerke, 1989, Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients, Acta Dermato-Venereologica. Supplementum, 146, 206
  90. Callis Duffin, 2017, Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A), Journal of the European Academy of Dermatology and Venereology : JEADV, 31, 107, 10.1111/jdv.13768 · doi:10.1111/jdv.13768
  91. Cassano, 2010, Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Talpharanta Plastic Study Group, International Journal of Immunopathology and Pharmacology, 23, 797, 10.1177/039463201002300314 · doi:10.1177/039463201002300314
  92. Cather, 2006, Efficacy and safety of low-dose acitretin for the treatment of moderate to severe plaque-type psoriasis. Abstract P2877. American Academy of Dermatology 64th Annual Meeting March 3-7, 2006, Journal of the American Academy of Dermatology, 54, AB217
  93. Chládek, 2002, Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis, British Journal of Clinical Pharmacology, 54, 147, 10.1046/j.1365-2125.2002.01621.x · doi:10.1046/j.1365-2125.2002.01621.x
  94. Chodorowska, 1999, Selected cytokines and acute phase proteins in psoriatic patients treated with cyclosporin A or Re-PUVA methods, Annales Universitatis Mariae Curie-Sklodowska. Section D: Medicina, 54, 173
  95. Chodorowska, 1999, Plasma levels of selected cytokines and acute phase proteins in 2 groups of psoriatic patients treated with cyclosporine A or RE-PUVA method. Abstract P-662. The 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands 29th Sept-3rd October 1999, Journal of the European Academy of Dermatology and Venereology : JEADV, 12, S330
  96. Jong, 2003, The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial, British Journal of Dermatology, 148, 318, 10.1046/j.1365-2133.2003.05173.x · doi:10.1046/j.1365-2133.2003.05173.x
  97. Dubiel, 1972, Experimental treatment with fumaric acid monoethylester in psoriasis vulgaris, Zeitschrift fur Haut- und Geschlechtskrankheiten, 47, 545
  98. Duffin, 2016, Comparison of the pharmacokinetics of ixekizumab following subcutaneous administration using a prefilled syringe versus an autoinjector in patients with moderate-to-severe psoriasis, Journal of the American Academy of Dermatology, 74, AB242
  99. Ecker-Schlipf, 2009, Psoriasis vulgaris: How effective and safe is the calcineurin inhibitor voclosporin?, Arzneimitteltherapie, 27, 97
  100. Ellis, 2002, Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate, Journal of the American Academy of Dermatology, 46, 242, 10.1067/mjd.2002.119196 · doi:10.1067/mjd.2002.119196
  101. Chow, 2012, Evaluation of Psoriasis Area and Severity Index, Static Physician's Global Assessment, and Lattice System - Physician's Global Assessment for assessing severity of psoriasis, Journal of the American Academy of Dermatology, 131, S81
  102. Engst, 1989, Results of cyclosporin treatment of severe, chronical psoriasis vulgaris, Hautarzt, 40, 486
  103. Erkko, 1997, Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis, British Journal of Dermatology, 136, 82, 10.1111/j.1365-2133.1997.tb08751.x · doi:10.1111/j.1365-2133.1997.tb08751.x
  104. Ezquerra, 2007, Combination of acitretin and oral calcitriol for treatment of plaque-type psoriasis, Acta Dermato-Venereologica, 87, 449, 10.2340/00015555-0290 · doi:10.2340/00015555-0290
  105. Fernandes, 2013, Maintenance treatment of psoriasis with cyclosporine A: comparison between continuous and weekend therapy, Journal of the American Academy of Dermatology, 68, 341, 10.1016/j.jaad.2012.08.013 · doi:10.1016/j.jaad.2012.08.013
  106. Italian Multicenter Study Group on Cyclosporin in Psoriasis, 1993, Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis., Dermatology (Basel, Switzerland), 187, 8, 10.1159/000247286 · doi:10.1159/000247286
  107. Fleischer, 2005, A randomized, double-blind, right/left comparative study of the efficacy of acitretin with and without the co-administration of 0.1 percent tacrolimus ointment in the treatment of moderate to severe psoriasis, Journal of Investigative Dermatology, 124, A46
  108. Fredriksson, 1971, Antipsoriatic activity of retinoic acid (vitamin A acid), Dermatologica, 142, 133, 10.1159/000252380 · doi:10.1159/000252380
  109. Friedrich, 2001, Addition of pentoxifylline could reduce the side effects of fumaric acid esters in the treatment of psoriasis, Acta Dermato-Venereologica, 81, 429, 10.1080/000155501317208408 · doi:10.1080/000155501317208408
  110. Gambichler, 2011, Etanercept plus narrowband ultraviolet b phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks, British Journal of Dermatology, 164, 1383, 10.1111/j.1365-2133.2011.10358.x · doi:10.1111/j.1365-2133.2011.10358.x
  111. Ganguly, 2004, Etanercept therapy provides clinically meaningful improvement in dermatology quality of life index in patients with chronic plaque psoriasis, Journal of the European Academy of Dermatology and Venereology: JEADV, 18, 807
  112. Gil, 2003, Association between calcitriol per os and acitretinoin in the treatment of psoriasis, Journal of the European Academy of Dermatology and Venereology: JEADV, 17, 383
  113. Goerz, 1978, Systemic treatment of psoriasis with a new aromatic retinoid. Preliminary evaluation of a multicenter controlled study in the Federal Republic of Germany, Dermatologica, 157, 38, 10.1159/000250883 · doi:10.1159/000250883
  114. Gollnick, 1988, Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study, Journal of the American Academy of Dermatology, 19, 458, 10.1016/S0190-9622(88)70198-X · doi:10.1016/s0190-9622(88)70198-x
  115. Gollnick, 1993, Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter half-year follow-up study, European Journal of Dermatology, 3, 442
  116. Gollnick, 2002, Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris, Dermatology (Basel, Switzerland), 205, 46, 10.1159/000063148 · doi:10.1159/000063148
  117. Gottlieb, 2002, Alefacept (AMEVIVETM) Does Not Blunt Primary or Secondary Immune Responses, Journal of Investigative Dermatology, 118, 1098
  118. Gottlieb, 2005, Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: A double-blind, multicentre, randomized, dose-finding trial, British Journal of Dermatology, 152, 1219, 10.1111/j.1365-2133.2005.06661.x · doi:10.1111/j.1365-2133.2005.06661.x
  119. Goupille, 1995, Is methotrexate really effective in patients with psoriatic arthritis?, Journal of Rheumatology, 22, 2369
  120. Griffiths, 1998, A double-blind, randomised trial to compare the effects of oral liarozole with acitretin in the treatment of chronic plaque psoriasis, British Journal of Dermatology, 139, 19
  121. Griffiths, 2002, Relationship between clinical response and quality of life in psoriasis patients treated with alefacept, Journal of the European Academy of Dermatology and Venereology : JEADV, 16, 292
  122. Griffiths, 2002, Effect of alefacept based on patients' response to prior therapy for psoriasis, British Journal of Dermatology, 147, 45
  123. Griffiths, 2005, A higher treatment standard for patients with moderate to severe psoriasis, Journal of the European Academy of Dermatology and Venereology : JEADV, 19, 7
  124. Grim, 2000, Pharmacokinetics (PK) and pharmacodynamics (PD) of low dose methotrexate (LDMTX) in the treatment of psoriasis, British Journal of Clinical Pharmacology, 50, 390
  125. Grossman, 1994, A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study, Journal of the American Academy of Dermatology, 31, 68, 10.1016/S0190-9622(94)70138-5 · doi:10.1016/s0190-9622(94)70138-5
  126. Gulliver, 1996, Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin, British Journal of Dermatology, Supplement, 135, 35, 10.1111/j.1365-2133.1996.tb00708.x · doi:10.1111/j.1365-2133.1996.tb00708.x
  127. Gupta, 2005, Comparative efficacy of methotrexate and hydroxyurea in treatment of psoriasis, Journal of Pakistan Association of Dermatologists, 15, 247
  128. Gupta, 2007, Methotrexate-betamethasone weekly oral pulse in psoriasis, Journal of Dermatological Treatment, 18, 291, 10.1080/09546630701487643 · doi:10.1080/09546630701487643
  129. Gupta, 2008, ISA247: quality of life results from a phase II, randomized, placebo-controlled study, Journal of Cutaneous Medicine and Surgery, 12, 268, 10.2310/7750.2008.07060 · doi:10.2310/7750.2008.07060
  130. Han, 2013, Sustained improvement in health-related quality of life, work productivity, employability, and reduced healthcare resource utilization of patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with golimumab: 5-year results from 3 phase iii studies, Arthritis and Rheumatism, 65, S137
  131. Hashizume, 2007, Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris, Journal of Dermatology, 34, 430, 10.1111/j.1346-8138.2007.00305.x · doi:10.1111/j.1346-8138.2007.00305.x
  132. Heule, 1988, Low-dose cyclosporine effective in severe psoriasis: a double-blind study, Transplantation Proceedings, 20, 32
  133. Ho, 2010, Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life, Clinical and Experimental Dermatology, 35, 717, 10.1111/j.1365-2230.2009.03693.x · doi:10.1111/j.1365-2230.2009.03693.x
  134. Hunter, 1972, A clinical trial of hydroxyurea for psoriasis, Australasian Journal of Dermatology, 13, 93, 10.1111/j.1440-0960.1972.tb00495.x · doi:10.1111/j.1440-0960.1972.tb00495.x
  135. Kavanaugh, 2009, The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis, Current Rheumatology Reports, 11, 233, 10.1007/s11926-009-0043-z · doi:10.1007/s11926-009-0043-z
  136. Koo, 1998, A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group, British Journal of Dermatology, 139, 88, 10.1046/j.1365-2133.1998.02319.x · doi:10.1046/j.1365-2133.1998.02319.x
  137. Kragballe, 1989, A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study, Acta Dermato-Venereologica, 69, 35
  138. Krueger, 1980, Comparison of labelling indices of skin involved and uninvolved with psoriasis: Placebo and oral retinoid RO 10-9359 vs. time, Clinical Research, 28, 21A
  139. Krueger, 2002, Pharmacodynamic effects of IM or IV Alefacept: Selective reductions in memory- effector (CD45RO+) cells are related to clinical improvement in psoriasis, Journal of Investigative Dermatology, 118, 1098
  140. Krueger, 2003, Repeated courses of IM alefacept in psoriasis: rationale and design of an international study that mimics the clinical practice setting, Journal of Investigative Dermatology, 121, 57
  141. Kuijpers, 1998, The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin, British Journal of Dermatology, 139, 380, 10.1046/j.1365-2133.1998.02399.x · doi:10.1046/j.1365-2133.1998.02399.x
  142. Lajevardi, 2015, The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial, International Journal of Dermatology, 54, 95, 10.1111/ijd.12585 · doi:10.1111/ijd.12585
  143. Langley R Leondardi C Okun M Long-term safety and efficacy of adalimumab in psoriasis 4th European Association of Dermatology & Venereology (EADV) Spring Symposium Saariselka, Lapland, Finland. February 9-12th, 2006 2006 P 021
  144. Langley, 2010, Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies, International Journal of Dermatology, 49, 818, 10.1111/j.1365-4632.2010.04512.x · doi:10.1111/j.1365-4632.2010.04512.x
  145. Langner, 2004, Results of a phase II study of a novel oral fumarate, BG-12, in the treatment of severe psoriasis., Journal of the European Academy of Dermatology and Venereology : JEADV, 18, 798
  146. Lawrence, 1983, Addition of retinoids to PUVA for psoriasis, Lancet, 1, 706, 10.1016/S0140-6736(83)91994-3 · doi:10.1016/s0140-6736(83)91994-3
  147. Leavell, 1970, Hydroxyurea. A new treatment for psoriasis, Archives of Dermatology, 102, 144, 10.1001/archderm.1970.04000080016003 · doi:10.1001/archderm.1970.04000080016003
  148. Lebwohl, 2003, The effect of psoriasis and its treatments on circulating T-cell subsets: results of alefacept studies, Journal of the European Academy of Dermatology and Venereology : JEADV, 17, 377
  149. Lebwohl M Kimball A Gordon K Szapary P Comparable efficacy and safety of ustekinumab in moderate to severe psoriasis patients previously treated with systemic therapies and treatment-naive patients Journal of the American Academy of Dermatology 2009 Supplemental
  150. Lebwohl, 2012, Safety and efficacy of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis, Dermatology and Therapy, 2, S39
  151. Lebwohl, 2013, A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis, Journal of the American Academy of Dermatology, 69, 385, 10.1016/j.jaad.2013.03.031 · doi:10.1016/j.jaad.2013.03.031
  152. Ledo, 1988, Acitretin (Ro 10-1670) in the treatment of severe psoriasis. A randomized double-blind parallel study comparing acitretin and etretinate, International Journal of Dermatology, 27, 656, 10.1111/j.1365-4362.1988.tb02429.x · doi:10.1111/j.1365-4362.1988.tb02429.x
  153. Legat, 2005, Alefacept plus 311 nm narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of psoriasis, Journal of Investigative Dermatology, 125, A4
  154. Leonardi, 2010, Characterization of infections associated with ustekinumab in moderate to severe psoriasis patients, Journal of the European Academy of Dermatology and Venereology, 24, 22
  155. Leonardi, 2010, Efficacy and safety of weekly adalimumab in psoriasis patients with a less than PASI 50 response to 40 mg every other week: Results from an open-label extension study, Journal of the European Academy of Dermatology and Venereology, 24, 9
  156. Leonardi, 2010, Long-term safety of adalimumab for psoriasis: An analysis of all adalimumab exposure in all global clinical trials, Journal of the European Academy of Dermatology and Venereology, 24, 26
  157. Leonardi, 2011, Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial, Archives of Dermatology, 147, 429, 10.1001/archdermatol.2010.384 · doi:10.1001/archdermatol.2010.384
  158. Levell, 1995, Remission of ordinary psoriasis following a short clearance course of cyclosporin, Acta Dermato-Venereologica, 75, 65, 10.2340/00015555756569 · doi:10.2340/00015555756569
  159. Liang, 1995, Combination therapy and the use of an initial dose of intramuscular methotrexate in patients hospitalized for psoriasis, Journal of Dermatological Treatment, 6, 73, 10.3109/09546639509097154 · doi:10.3109/09546639509097154
  160. Lui, 2011, Efficacy and safety of alefacept in combination with narrowband uvb compared to alefacept alone in subjects with moderate to severe psoriasis: results of the Canadian alefacept phototherapy psoriasis study, Journal of the American Academy of Dermatology, 64, AB150
  161. Lui, 2012, A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response, Journal of Drugs in Dermatology, 11, 929
  162. Lynde, 2012, A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept, Journal of Dermatological Treatment, 23, 261, 10.3109/09546634.2011.607795 · doi:10.3109/09546634.2011.607795
  163. Macdonald, 1972, Retinoic acid in the treatment of psoriasis, British Journal of Dermatology, 86, 524, 10.1111/j.1365-2133.1972.tb16108.x · doi:10.1111/j.1365-2133.1972.tb16108.x
  164. Mahrle, 1995, Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement, Journal of the American Academy of Dermatology, 32, 78, 10.1016/0190-9622(95)90189-2 · doi:10.1016/0190-9622(95)90189-2
  165. Malik, 2010, Comparison of methotrexate and azathioprine in the treatment of psoriasis: A randomized controlled trial, Journal of Pakistan Association of Dermatologists, 20, 152
  166. McInnes, 2013, Safety of ustekinumab from the placebo-controlled periods of psoriatic arthritis and psoriasis clinical developmental programs, Arthritis and Rheumatism, 72, Suppl
  167. Meffert, 1989, Acitretin in the treatment of severe psoriasis: a randomized double-blind study comparing acitretin and etretinate, Acta Dermato-Venereologica. Supplementum, 146, 176
  168. Menon, 2012, Single and multiple-dose pharmacokinetics of tofacitinib (CP-690,550) from a double-blind, placebo-controlled, dose-escalation study in medically stable subjects with psoriasis, Clinical Pharmacology and Therapeutics, 91, S33
  169. Menter, 2007, Efficacy of infliximab in patients with severe psoriasis: Subgroup analysis from clinical trials, Journal of the American Academy of Dermatology, 56, AB174
  170. Menter, 2014, Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions, Journal of Drugs in Dermatology, 13, 252
  171. Meyer, 2011, Immunogenicity of tumour necrosis factor inhibitors in patients with psoriasis receiving long-term treatment, British Journal of Dermatology, 165, e17
  172. Moller, 2009, Efficacy of leflunomide in patients with psoriatic arthritis, Seminarios de la Fundacion Espanola de Reumatologia, 10, 48
  173. Monk, 1986, Cyclosporin A and psoriasis, British Journal of Dermatology, 115, 249, 10.1111/j.1365-2133.1986.tb05727.x · doi:10.1111/j.1365-2133.1986.tb05727.x
  174. Montgomery, 1993, BCX-34. Purine nucleoside phosphorylase (PNP) inhibitor, Drugs of the Future, 18, 887, 10.1358/dof.1993.018.10.222285 · doi:10.1358/dof.1993.018.10.222285
  175. Mrowietz, 1991, Low-dose ciclosporin A (Sandimmun) in psoriasis: A multicenter dose-finding study, Zeitschrift fur Hautkrankheiten, 66, 25
  176. Mrowietz, 2012, Achievement of European Consensus Programme treatment goals in three clinical trials of adalimumab in moderate-to-severe psoriasis, Journal of the American Academy of Dermatology, 66, AB183
  177. Narang, 2012, Serendipity opens new avenues: A pilot study to evaluate the efficacy of saxagliptin in combination with cyclosporine and acitretin in diabetic psoriasis patients, Dermatology and Therapy, 2, S36
  178. Noda, 2011, Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single community-based hospital, Journal of Investigative Dermatology, 131, S38
  179. Nyfors, 1978, Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics, Danish Medical Bulletin, 25, 208
  180. Orfanos, 1978, Oral psoriasis treatment with a new aromatic retinoid (Ro 10-9359): a multi-centre controlled study of 291 patients (preliminary results), Deutsche Medizinische Wochenschrift, 103, 195, 10.1055/s-0028-1104405 · doi:10.1055/s-0028-1104405
  181. Orfanos, 1979, Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis, Acta Dermato-Venereologica, 59, 241, 10.2340/0001555559241244 · doi:10.2340/0001555559241244
  182. Ortonne, 2008, Efficacy and safety of continuous versus paused etanercept teatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL Study, Expert Review of Dermatology, 3, 657, 10.1586/17469872.3.6.657 · doi:10.1586/17469872.3.6.657
  183. Ortonne, 2011, Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE, Journal of the European Academy of Dermatology and Venereology : JEADV, 25, 1012, 10.1111/j.1468-3083.2010.03944.x · doi:10.1111/j.1468-3083.2010.03944.x
  184. Papp, 2001, The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody, Journal of the American Academy of Dermatology, 45, 665, 10.1067/mjd.2001.117850 · doi:10.1067/mjd.2001.117850
  185. Papp, 2006, A Phase III, randomized, multicenter, double-blind, placebo-controlled, Journal of the American Academy of Dermatology, 54, AB9
  186. Papp, 2009, Adalimumab in the treatment of psoriasis: Pooled efficacy and safety results from three pivotal studies, Journal of Cutaneous Medicine and Surgery, 13, S58, 10.2310/7750.2009.00022 · doi:10.2310/7750.2009.00022
  187. Papp, 2011, Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept, Journal of the American Academy of Dermatology, 64, AB153
  188. Papp, 2011, Effects of abt-874 treatment on health-related quality of life and work productivity and activity impairment in patients with psoriasis, Journal of the American Academy of Dermatology, 64, AB155
  189. Papp, 2011, Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with abt-874, Journal of the American Academy of Dermatology, 64, AB160
  190. Paul, 2012, Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study, European Journal of Dermatology, 22, 762, 10.1684/ejd.2012.1863 · doi:10.1684/ejd.2012.1863
  191. Paul, 2014, Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: A randomized clinical trial (TRANSIT), British Journal of Dermatology, 170, 425, 10.1111/bjd.12646 · doi:10.1111/bjd.12646
  192. Pettit, 1979, Oral retinoid for psoriasis. A report of a double blind study, Acta Dermato-Venereologica. Supplementum, 59, 133
  193. Petzelbauer, 1990, Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis, British Journal of Dermatology, 123, 641, 10.1111/j.1365-2133.1990.tb01481.x · doi:10.1111/j.1365-2133.1990.tb01481.x
  194. Piascik, 2003, Alefacept, first biologic agent approved for treatment of psoriasis, Journal of the American Pharmacists Association, 43, 649, 10.1331/154434503322452328 · doi:10.1331/154434503322452328
  195. Rabasseda, 2012, A report from the American Academy of Dermatology 70th Annual Meeting (March 16-20, 2012 - San Diego, California, USA), Drugs of Today, 48, 367, 10.1358/dot.2012.48.5.1811774 · doi:10.1358/dot.2012.48.5.1811774
  196. Raman, 1998, Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis, Journal of Hypertension. Supplement, 16, S39
  197. Reich, 2011, Long-term efficacy and safety of maintenance versus intermittent infliximab therapy for moderate to severe plaque-type psoriasis: the restore2 trial, Journal of the American Academy of Dermatology, 64, AB150
  198. Reich, 2014, One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis, British Journal of Dermatology, 170, 435, 10.1111/bjd.12643 · doi:10.1111/bjd.12643
  199. Reitamo, 1999, A double-blind study in patients with severe psoriasis to assess the clinical activity and safety of Rapamycin (sirolimus) alone or in association with a reduced dose of cyclosporine, British Journal of Dermatology, 141, 978
  200. Rim, 2003, The efficacy of calcipotriol + acitretin combination therapy for psoriasis: comparison with acitretin monotherapy, American Journal of Clinical Dermatology, 4, 507, 10.2165/00128071-200304070-00006 · doi:10.2165/00128071-200304070-00006

200 of 259 shown

Cited by

See all 433

Metadata

Authors
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., Chosidow, O., & Le Cleach, L.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-12-22
Volume
12
Pages
CD011535-CD011535
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2781078917
Cited by
433
References
327
FWCI
14.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. https://app.cochat.ai/papers/10.1002/14651858.cd011535.pub2
The paper
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., Chosidow, O., & Le Cleach, L. (2017). Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011535.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.